GenMark Diagnostics (GNMK) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Needham & Company Reiterates a Buy Rating as GenMark Diagnostics (GNMK) Reports 4Q Results Consistent with Preannouncement
February 24, 2016 10:36 AM ESTNeedham & Company maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $11.00 (from $13.00), following the company's 4Q earnings report. Revenue was $13.2M vs. consensus of $8.2M and GAAP EPS was ($0.21) vs. consensus of ($0.27). GNMK guided to 2016 revenue of... More
